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ADRs included seriousness of reaction (75.8%), unusual reaction (63.6%), reaction 
to a new product (66.6%) and confidence in the diagnosis of ADR (31.5%). Similarly, 
the discouraging factors are uncertain association (65.7%), awareness (57.6%), and 
concern about legal liability (51.4%). ConClusions: It is observed that awareness 
of ADRs program need special attention with some concrete steps should be taken 
for the improvement of ADRs system in Pakistan. Continuing medical education, 
training and integration of ADRs reporting into the clinical activities would defi-
nitely improve the patient outcome.
PIH70
Assessment Of HeAltH stAtes And erectIle dysfunctIOn-AssOcIAted 
QuAlIty Of lIfe AmOng Adult unIted stAtes mAles And unIted stAtes 
femAles WItH mAle PArtners
Wasserman D., Bonus T., Bakken D.G., Tomaszewski K.
KJT Group, Inc., Honeoye Falls, NY, USA
objeCtives: This study assessed the quality of life associated with erectile dysfunc-
tion (ED) among the U.S. adult population both among diagnosed ED sufferers and 
non-sufferers. Methods: A representative (U.S.) sample of 1,000 adults (502 males, 
498 females) completed an online survey about their own (for men) or partner’s (for 
women in a heterosexual relationship) overall and erectile function health states 
and quality of life. Health states utilities were measured using both SG and VAS 
questions (counterbalanced order). Results: 11.3% of males report having been 
diagnosed with ED and 6.4% of females report that their male partner has been 
diagnosed. Overall, the SG and VAS measures yield very similar but not identical 
utility estimates for the ED health state. The mean utility estimates across all eligible 
respondents are 0.41 (0-1 scale) for the SG and 0.44 for the VAS. Looking just at SG, 
males have lower utility on average (0.37) for the ED health state than do females for 
their partner’s ED health state and there was no difference between males who are 
healthy and those diagnosed with ED. Women whose partners are healthy express 
lower utility for the ED health state (described as “significant difficulty in achieving 
an erection/penis gets hard but not hard enough for penetration”) than women with 
a partner diagnosed with ED. Younger respondents also have lower utility for the ED 
state than older respondents, and for the VAS the utility function across 5 levels of 
ED is linear. ConClusions: The fact that males who have not been diagnosed with 
ED have the same utility for the ED health state as those who have been diagnosed 
indicates that otherwise healthy males accurately anticipate quality of life decline 
associated with ED. Females with a diagnosed partner seem more willing to accept 
living with that partner’s ED health state.
PIH72
sPOnsOrIng sPAnIsH lAnguAge trAnslAtIOns In unIted stAtes-BAsed 
clInIcAl trIAls
Popielnicki A.1, Nakonechny A.2, Sydor B.2, Dawsey R.3, Shi Y.4
1TransPerfect, MA, 2TransPerfect, New York, NY, USA, 3TransPerfect, Atlanta, GA, USA, 4ProPhase, 
LLC
objeCtives: The accuracy of clinical trial data can be jeopardized if the trans-
lations used in the study are not regionally appropriate, particularly if the COAs 
(Clinical Outcomes Assessments) record direct feedback from patients whose first 
language is not English. Ensuring regional sensitivity in translations can be diffi-
cult in countries like the United States, where four major dialect groups dominate 
the Spanish influence. The purpose of this poster is to review best practices for 
conducting linguistic validation for US-based sites to ensure the most appropri-
ate Spanish language is used. Methods: Past studies that required US Spanish 
were reviewed to analyze specific selections and locations of Spanish-speaking 
patients. Consideration was given to studies incorporating multiple site locations 
around the country, as well as to studies targeting a specific region. Results: US 
Spanish translations yielded the best results when site location was communicated 
to the linguistic validation provider. When this information is not available at project 
commencement, it is necessary to consider the array of national backgrounds and 
subsequent cultural correlations that are present throughout the US when select-
ing translators and cognitive interviewing respondents. When site locations were 
throughout the US, the most inclusive and universal US Spanish was achieved with 
the following cognitive debriefing recruitment formula for a 5 respondent inter-
view: 2 Mexican respondents, 1 South American respondent, 1 Central American 
respondent, and 1 Caribbean respondent. If site locations are being concentrated 
in one area, selecting a team that represents the largest population in that region 
is ideal. ConClusions: Determining US site location prior to translation is recom-
mended to ensure a more comprehensive translation that is tailored toward the 
target population, therefore yielding the most accurate responses. If sites have not 
been confirmed within the US, a recruitment formula developed to account for 
major Spanish populations in the US is recommended.
PIH73
stress (PerceIved And AcculturAtIve) And HeAltH relAted QuAlIty Of 
lIfe AmOng students In tHe IsPOr student netWOrk: A PIlOt study
Ogunsanya M.E.1, Sudhapalli P.1, Thach A.V.1, Bamgbade B.1, Rascati K.L.2
1The University of Texas at Austin, College of Pharmacy, Austin, TX, USA, 2The University of 
Texas at Austin, Austin, TX, USA
objeCtives: The objective of this pilot study was to investigate the associations 
among perceived stress, acculturative stress, coping mechanisms, and health-
related quality-of-life of graduate students. Methods: A cross-sectional, self-
administered questionnaire was distributed to UT-ISPOR graduate students. 
Participants were recruited using an email cover letter sent through the UT-ISPOR 
mailing list. Willing participants were asked to complete the survey (either web-
based or paper-pencil method). The questionnaire consisted of five sections: 1) 
SF-12 Health Survey (mental component summary [MCS], and physical component 
summary [PCS]); In the general population, these scores have a mean of 50 and 
a standard deviation of 10, with higher scores correlating with better HRQoL; 2) 
Graduate Stress Inventory-Revised (GSI-R) Scale (higher scores = higher stress) ; 
PIH67
A revIeW Of PAtIent-rePOrted OutcOme OrPHAn drug lABels In 
tHe unIted stAtes frOm JAnuAry 2006-sePtemBer 2013: AnAlysIs Of 
evIdence fOr OrPHAn drug PrO lABel clAIms
Clark M.1, Simons C.2, Haydysch E.1, DeMuro C.3, Gnanasakthy A.4
1RTI Health Solutions, Ann Arbor, MI, USA, 2University of Michigan, Ann Arbor, MI, 3RTI Health 
Solutions, Research Triangle Park, NC, USA, 4Novartis Pharmaceuticals, East Hanover, NJ, USA
objeCtives: Previous reviews of patient-reported outcome (PRO) label claims did 
not distinguish products with orphan designation. Prior analyses suggest less evi-
dence is required for orphan drug approvals compared to non-orphan drugs. This 
study aimed to identify orphan drug products approved by the US Food and Drug 
Administration (FDA) between 2006 and 2013, prevalence of PRO label claims for 
these products, and evidence supporting PRO claim approval. Methods: Using the 
Drugs@FDA database, new molecular entities and biologic licensed agents approved 
between January 2006 and September 2013 with orphan review classification were 
identified, with subsequent label review. For products with PRO label claims, medical 
and summary review sections from FDA drug approval packages were reviewed to 
identify reviewing division, indication, review designation (priority, standard), PRO 
endpoint status, PRO measure type, number of phase 3 trials supporting claims, and 
PRO-related SEALD comments. Descriptive data were recorded in Microsoft Excel; 
frequency of measured characteristics was analyzed. Results: Of 43 orphan prod-
ucts identified, 5 (12%) included PRO label claims. Five orphan products achieved 
7 PRO claims. Priority and standard review prevalence were similar (44% vs. 40%, 
respectively) for orphan products; the majority (4 of 5) of products with PRO claims 
were priority review. A slight majority (60%; 3 of 5 orphan products) included PRO 
claims supported by ≤ 1 phase 3 trial. Signs/symptoms measures and secondary 
PRO endpoints were most common (57% each). FDA reviewing division varied. One 
product received PRO-related SEALD comments. ConClusions: For the time period 
evaluated, orphan products rarely included a PRO label claim. These claims may 
not be needed for orphan product differentiation to the degree that they are for 
non-orphan products. PRO claims achieved for orphan products appear to require 
less supporting evidence for approval than non-orphan products, consistent with 
orphan drug approval expectations but in contrast to FDA PRO guidance criteria.
PIH68
HeAltH OutcOmes AssOcIAted WItH tHe use Of PrOHOrmOne 
nutrItIOnAl suPPlements
Noone J.1, Blanchette C.M.1, Huet Y.1, Howden R.1, Saunders W.B.2, Langford D.1
1University of North Carolina at Charlotte, Charlotte, NC, USA, 2University of North Carolina, 
Charlotte, NC, USA
objeCtives: Anabolic prohormones, similar to anabolic-androgenic steroids, are 
sold as dietary supplements in the United States. There is very little known about 
the health outcomes associated with exposure to prohormones. The objective of 
this study was to assess health outcomes and user perceptions about health out-
comes associated with prohormone use. Methods: A self-administered survey was 
developed and deployed via two e-forums dedicated to prohormone use. Questions 
included information about health outcomes, beliefs about the commonality of 
side effects in users, and prohormone use characteristics including number of sub-
stances taken, number of cycles completed in a year, and taking the recommended 
or excess dosage. Outcomes were correlated with beliefs. Logistic regressions were 
used to measure the association between dose categories and self-reported out-
comes. A multiple risk factor analysis looked at the association between higher than 
average number of self-reported outcomes and several combined risk indicators. 
Combined risk indicators comprised of taking above recommended dose merged 
in combination with highest number of substances per cycle, highest number of 
cycles per year and having also taken AAS in the last year, respectively. Results: 
Eighteen self-reported outcomes were generated from 65 responders. Users reported 
an average of 2.49 (SD-0.60) outcomes in their last prohormone cycle. Correlations 
showed those who experienced no outcomes believe adverse events are uncom-
mon (R= 0.26, P= 0.04). Conversely, those who experienced the highest number of 
outcomes are not correlated with the belief that outcomes are common (R= 0.17.
P= 0.16). No outcome was significantly associated with taking more than the rec-
ommended dose. Multiple risks showed no significant association with an above 
average number of reported outcomes. cOnclusIOns: This study is a pilot into an 
understudied population. Despite having a small sample, this study is the first of 
its kind in compiling self-reported outcomes in prohormone users.
PIH69
Adverse drug reActIOn rePOrtIng system At dIfferent HOsPItAls Of 
lAHOre - An evAluAtIOn And PAtIent OutcOme AnAlysIs
NazirS.U.R. 
Universiti Sains Malaysia, Sargodha, Pakistan
objeCtives: ADRs are known to be a major cause of morbidity and mortality. 
However, only a very little proportion is reported. ADRs contribute to the incidence 
of adverse events, resulting in increased health care costs. Methods: The first 
part of this project was to review the ADRs reporting system in Pakistani hospitals, 
to determine the factors contributing to the ADR reporting rate and benchmark 
with developed countries. Data was collected by self-administered questionnaire. 
24 (80%) hospitals have no proper ADRs system; five (16.7%) hospitals are targeting 
few of the drugs for ADRs reporting while only one (3.3%) hospital has a proper ADRs 
policy including online reporting system as well. Only seven (23.3%) hospitals have 
a policy of ADRs reporting. The next part of the project was a survey of 84 doctors 
and 52 Pharmacists selected from Lahore, Pakistan to evaluate their involvement, 
understanding and reasons for reporting ADRs. A self-administered questionnaire 
was used to collect the data. Results: Response rate obtained for the doctors 
was (39.3% n= 33) and (67.3% n= 35) for hospital pharmacists. Thirty three (39.3%) 
doctors and thirty four (65.4%) pharmacists knew how to report ADRs within the 
hospital while 9 (10.7%) doctors and 13 (25%) Pharmacists knew about the ADRs 
reporting to Ministry of Health. Factors that would encourage respondents to report 
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age group (< 18, 18–34, 35+), race, ethnicity, number of high-risk diagnosis codes, 
and zip codes. High-risk diagnoses—including prior history of preterm delivery, 
insulin-dependent diabetes, hypertension, multiple gestations, and incompetent 
cervix—are known predictors of low birth weight and premature delivery. Results: 
Thirty-one participants at high-risk for premature delivery received cell phones and 
text-messaging services. Twenty-six mothers (84%) successfully delivered babies to 
term (< 31 days from expected delivery date). Babies born in the IG had higher birth 
weights than those born in the CG (mean, 38.71g), lower rates of low birth weight 
babies (-0.12%) and very low birth weight babies (-0.06%), and delivered almost a 
full week later (mean, 0.96 wk). Participants reported high program-satisfaction 
rates. ConClusions: Members at high risk for preterm delivery participating in 
Moms2B had superior pregnancy outcomes compared to nonparticipants; program 
satisfaction was favorable.
PIH77
vAlue Of InfOrmAtIOn AnAlysIs tO determIne PrIOrItIes Of future 
reseArcH fOr lng-Ius 13.5 mg cOntrAcePtIve
Chuang L.H.1, Treur M.1, Law A.W2, Filonenko A.3
1Pharmerit International, Rotterdam, The Netherlands, 2Bayer HealthCare Pharmaceuticals Inc, 
Whippany, NJ, USA, 3Bayer Pharma AG, Berlin, Germany
objeCtives: To apply value of information analysis (VoI) to a cost-effectiveness 
model of a Levonorgestrel intrauterine system LNG-IUS 13.5mg (total content) in 
order to identify parameters worth investigating to reduce remaining uncertainty 
around the reimbursement decision. LNG-IUS 13.5mg is a novel low-dose hormonal 
intrauterine contraceptive system for up to 3 years use and was shown to be cost-
effective over this horizon vs. commonly used short-acting contraceptive methods 
in women aged 20-29. Methods: VoI analyses were performed using an exist-
ing US cost-effectiveness model with LNG-IUS 13.5mg. Expected Value of Perfect 
Information (EVPI) and the parameter EVPIs (EVPPI) for the following groups were 
estimated: probability of failure (unintended pregnancy (UP)); probability of discon-
tinuation during year 1 and subsequent years; and follow-up consultation costs. 
Individual EVPPIs were calculated for probability of failure of injectable contracep-
tives and LNG-IUS 13.5mg and first year discontinuation probability of LNG-IUS 
13.5mg. EVP(P)I were calculated using different willingness to pay (WTP) values for 
an UP and extrapolated to population values. Results: The estimated EVPI was 
$69, $62 and $40 at WTP of $300, $400 and $700 per UP, respectively. EVPPI analysis 
suggested that probabilities of failure and first year discontinuation were the most 
influential, accounting for the majority of uncertainty of the reimbursement deci-
sion. Population EVPI estimates suggested that further research in this area was 
potentially worthwhile. ConClusions: Comparative effectiveness research focus-
ing on the failure rate of injectable contraceptives and the first year discontinuation 
rate of LNG-IUS 13.5mg is potentially worthwhile. Expected value of sample informa-
tion will have to be compared to the actual costs of such research.
PIH79
neOnAtAl InfOrmAtIOn On APPrOved drug lABels: An AnAlysIs Of 
cOnsIstency In drug lABelIng
Nambiar S.1, Lindberg-Springs S.1, Seoane-Vazquez E.2
1Massachusetts College of Pharmacy & Health Sciences University, Boston, MA, USA, 
2International Center for Pharmaceutical Economics and Policy, Massachusetts College of 
Pharmacy and Health Sciences, Boston, MA, USA
objeCtives: The paucity of pediatric information available on drug labels has-
tened calls for regulatory intervention aimed at providing clinicians with improved 
information to treat pediatric populations, especially neonates. This study exam-
ined how neonatal drug data is presented on labels for approved drugs over the 
past 30 years. Methods: This study included review of publicly available data 
retrieved from the FDA website Drugs@FDA. Three sections of the FDA approved 
label were analyzed for mention of neonates; “Indication and Usage”, “Dosage and 
Administration” and “Pediatric Use”. “Neonates” were defined as infants age 0-28 
days and/or specifically cited as “neonates” or “newborns”. This analysis did not 
include label information pertinent to in utero exposure to drug. Descriptive sta-
tistics were performed and the pharmaceutical active ingredient was the unit of 
analysis. Results: The study included all NDA/BLA approvals by the FDA between 
January 1, 1980 and December 31, 2012 and available on the Drugs@FDA website 
(n= 676). Eleven (1.6%) labels included neonate information in the Indications and 
Usage section, 33 (4.9%) in the Dosage and Administration section and 62 (9.2%) 
in the Pediatric Use section. References to neonates occurred in two sections on 2 
labels (0.3%) and in all three sections on 5 labels (0.7%). Statements that the drug 
was not studied and/or not recommended in neonates were most often found in the 
Pediatric Use section (528, 78%), but also noted in the Dosage and Administration 
section (22, 3.3%) and the Indications and Usage section (9, 1.3%). ConClusions: 
This study demonstrates that data necessary to determine the appropriateness 
of medications in neonates is difficult to find, even when available to clinicians. 
As regulators consider how to improve the quantity and quality of neonatal drug 
data, consideration should be given to standardizing neonatal information on drug 
labels, thereby ensuring that regulatory efforts to incentivize pediatric research 
are optimized.
PIH80
HeAltH cAre utIlIzAtIOn And cOsts AmOng PrIvAtely Insured 
cHIldren WItH OrOfAcIAl clefts
Chung J.K., Cassell C.H., Honein M.A., Olney R.S., Grosse S.D.
Centers for Disease Control and Prevention, Atlanta, GA, USA
objeCtives: Orofacial clefts (OFC) are among the most common birth defects and 
often require hospitalizations during early childhood. We assessed health care 
utilization and costs for children during 2010. Methods: Data were extracted 
from the 2006-2010 MarketScan® Commercial claims databases to identify children 
with ≥ 2 outpatient claims or ≥ 1 inpatient claim for OFC during those five years 
to maximize case ascertainment. Health care utilization and costs during 2010 
3) Brief COPE Scale (higher scores = better coping); 4) Acculturative Stress (ASSIS) 
(higher scores = higher stress) [For international students only] and; 5) demographic 
information. Results: The mean age of the 19 participants was 28.9 years ± 4.6. A 
majority of the respondents were Asian (47.4%), female (73.7%), enrolled in the PhD 
program (73.7%), single (52.6%), international students (57.9%) and lived with family 
(47.4%). Mean PCS and MCS were 49.97 ± 9.3 and 49.97 ± 8.22, respectively, indicating 
that both the physical health and mental health summary scores were comparable 
to the general population. Overall, participants reported low stress (GSI-R) levels 
(mean= 56.53 ± 20.3; range 21 – 147)) and engaged in mid-range levels of coping 
mechanisms to deal with stress (mean= 71.42 ± 7.1; range 28 – 140). Among inter-
national students, acculturative stress levels (mean= 51.10 ± 27.9; range 36 – 180) 
were low. ConClusions: There is a paucity of quantitative data for perceived stress 
among graduate students. The results from this pilot study will be used to imple-
ment a future survey among a larger and more diverse sample of graduate students.
PIH74
A sImPle And effectIve APPrOAcH fOr AnAlyzIng multIvArIAte 
lOngItudInAl HeAltH OutcOmes In OBservAtIOnAl studIes
Kuhn E.1, Spielmann R.1, Ochs L.1, Koh W.Y.2, Tu C.1
1University of New England, Portland, ME, USA, 2University of New England, Biddeford, ME, USA
objeCtives: The purpose of this paper is to propose a simple and efficient approach 
for analyzing multivariate longitudinal data (MLD), such as longitudinal health-
related quality of life (HRQoL) assessments in observational studies. This will be 
accomplished using the combination of two popular statistical methods for causal 
inference and multivariate data, namely the inverse probability-weighted (IPW) esti-
mator and principal component analysis (PCA). Methods: Multivariate outcomes 
at each time point will be converted to the first principal component score (FPCS) for 
each subject. Then all FPCS will be composited into a numerical observation using 
the area under a curve (AUC). The IPW estimator is used to compare the difference 
between the two treatments in terms of the estimated AUCs. Finally, the proposed 
method will be applied to a simulated dataset to determine if there is significant 
difference between two treatments. Results: The statistical results show that the 
95% bootstrap percentile confidence interval (BPCI) is (-3.06, -3.59). Since the BPCI 
does not contain zero, we claim that the treated group (M= 1) is significantly differ-
ent from the control group (M= 0) at a 5% level in overall longitudinal multivariate 
health outcomes. ConClusions: In this paper, we propose a simple and efficient 
approach to overcome the difficulty of analyzing MLD in practice. We demonstrate 
how to use our proposed method with a simulated dataset. Our simulated data set 
allowed us to demonstrate how our proposed method may be particularly useful 
for analyzing longitudinal HRQoL assessments in medical studies.
PIH75
Assessment Of medIcAl And PHArmAcy students’ knOWledge And 
PercePtIOns ABOut generIc medIcInes And tHeIr QuAlIty And PrIces In 
kABul – AfgHAnIstAn
Bashaar M., Ahmad Hassali M.A.
Universiti Sains Malaysia, Penang, Malaysia
objeCtives: To assess medical and pharmacy students’ knowledge and perception 
about generic medicines and its quality and prices in Kabul- Afghanistan. Methods: 
A questionnaire based convenience sample of 255 was applied and study was con-
ducted at Kabul Medical University and Pharmacy Faculty of Kabul University. The 
questionnaire had 19 questions and was designed in two sections (definition of 
generic and branded medicine and perception towards generic medicine). A total 
of 95 pharmacy and 125 medical students had voluntarily participated in the sur-
vey. SPSS version 16 was used for data analysis purposes. Results: Among the 
total target n = 220 (response rate 86.27%) students voluntarily participated in the 
survey and n = 27 (28.42%) of the pharmacy students were working as pharmacists 
in the private pharmacy outlets. In reference to the knowledge about generic medi-
cines n = 173 (67.84%) of the respondents had knowledge about generic medicines. 
The interviewees n = 205 (80.39%) expressed that the quality is their major con-
cern, when buying generic medicines. Both groups have shown unanimity n= 216 
(84.70%) that prescription of generic medicines promotes cost containment among 
the patient. ConClusions: The current study emphasizes that awareness and 
knowledge about generic medicines by including special topics in the medical and 
pharmacy curriculum is important and further promoting culture of prescribing 
generic medicines in daily practice.
IndIvIduAl’s HeAltH – Health care use & Policy studies
PIH76
mOms2B: ImPrOvIng BIrtH OutcOmes tHrOugH use Of cell PHOnes, 
textIng, And IntensIve cAse mAnAgement
Grant M., Stango D.A., Anthony D., Dinsmore S., Keleti D., Michael K.E., Tan-Torres S.
AmeriHealth Caritas Family of Companies, Philadelphia, PA, USA
objeCtives: Out of 200 of the most populous U.S. counties, Philadelphia has the 
fifth highest infant mortality rate. Keystone First partnered with Verizon Wireless 
to launch Moms2B—a program providing free cell phones and minutes to directly 
engage Keystone First’s high-risk pregnant Medicaid members. The goals are to 
improve prenatal care and health outcomes, and keep members connected to 
the plan’s Bright Start® maternity program. Methods: The Bright Start Care 
Management team contacted participants on the cell phones to provide coach-
ing and care coordination during pregnancy and postpartum. Participants also 
received text messages with nutritional and clinical information specific to gesta-
tional age. In addition, they received encouragement and gift incentives to main-
tain scheduled prenatal/postpartum care, along with information about screenings, 
and educational and community-based programs. Seventeen participants actively 
engaged in Moms2B (intervention group: IG) were risk-matched to 17 nonparticipat-
ing high-risk pregnant members (control group: CG). Matching variables included 
